A Case of Advanced Gastric Cancer with Peritoneal Metastasis Treated Successfully with Nivolumab

• DOI: 10.1159/000501717
• Publication Date: 2019-07-16T21:00:44Z
• Authors: Hirofumi Tazawa; Takahisa Suzuki; Toshiaki Komo; Haruna Kubota; Shunya Tahara; Haruki Sada; Naoto Hadano; Wataru Shimizu; Kohei Ishiyama; Takashi Onoe; Takeshi Sudo; Yosuke Shimizu; Hirotaka Tashiro
• Keywords: 03 medical and health sciences; Advanced gastric cancer; Nivolumab; 0302 clinical medicine; Peritoneal metastasis; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; Case Report; RC254-282; 3. Good health

Peritoneal metastasis (PM) is detected in 14% of gastric cancers at the time initial diagnosis, with a median survival 4 months. A 66-year-old woman diagnosed cT4a(SE) N2M1(LYN) cStage IV was treated three lines chemotherapy for year. During third line chemotherapy, computed tomography (CT) scan revealed large amount ascites, periportal collar sign, and bilateral ureteral stenosis owing to PM. The tumor biomarkers (CEA CA 19-9) remained elevated similar levels. patient administered 3 mg/kg nivolumab intravenously biweekly as fourth chemotherapy. Three months after treatment, gastroscopy an extreme reduction size, while CT absence ascites well-controlled tumor. There no immune-related adverse event during performance status improved 0. has been alive about 2.5 years since her first visit sixth (docetaxel). We report case advanced cancer PM that successfully nivolumab.